Before initiating clinical studies targeting PAR-1 in the setting of diabetic nephropathy it is therefore pivotal to establish whether pharmacological inhibition of PAR-1, started once diabetes has been established, also limits diabetes-induced kidney damage. Here, F2R is linked to diabetic kidney disease.